Recent Updates
Recently added Catalysts
CRIS Neutral Sentiment

UCLA Department of Medicine – Hematology/Oncology

Key Takeaway: The article provides an overview of the UCLA Department of Medicine's Hematology/Oncology division, detailing its management structure, collaborations, patient studies, and pipeline of drug candidates. It highlights various current studies, including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL, along with information on scientific resources and investor relations. The article serves as a comprehensive guide to the department's activities and offerings.
Price reaction · baseline $109 (2024-10-22 close) · hit pre-market · 27 other CRIS headline(s) in the window, move may be shared
day 0 close · peak
-4.2%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~1 mo
High dilution risk
Lead asset
Emavusertib
Phase 2 · Chronic Lymphocytic Leukemia

Full Press Release Details

• About Company Overview Management Board of Directors Advisory Boards
• Collaborations Partner Collaborations Scientific & Research Collaborations
• Patients Patients Overview Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL Understanding Primary CNS Lymphoma Compassionate Use Policy
• Pipeline Pipeline Overview Emavusertib (CA-4948) Fimepinostat CA-170 CA-327
• Scientific Resources
• Investors Overview Press Releases Events and Presentations Corporate Governance Committee Composition Contact the Board Financial Information SEC Filings Annual Reports IRS Form 8937 Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage Contact Us
• Careers Life at Curis Open Positions Benefits
• Contact
• Company Overview
• Management
• Board of Directors
• Advisory Boards
• Partner Collaborations
• Scientific & Research Collaborations
• Patients Overview
• Current Studies Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• Understanding Primary CNS Lymphoma
• Compassionate Use Policy
• Sponsored TakeAim Lymphoma TakeAim Leukemia TakeAim CLL
• TakeAim Lymphoma
• TakeAim Leukemia
• TakeAim CLL
• Pipeline Overview
• Emavusertib (CA-4948)
• Fimepinostat
• CA-170
• CA-327
• Overview
• Press Releases
• Events and Presentations
• Corporate Governance Committee Composition Contact the Board
• Financial Information SEC Filings Annual Reports IRS Form 8937
• Stock Performance Interactive Chart Historical Stock Lookup Analyst Coverage
• Contact Us
• Committee Composition
• Contact the Board
• SEC Filings
• Annual Reports
• IRS Form 8937
• Interactive Chart
• Historical Stock Lookup
• Analyst Coverage
• Life at Curis
• Open Positions
• Benefits

Frequently Asked Questions

What studies are sponsored by UCLA's Hematology/Oncology?

UCLA sponsors studies including TakeAim Lymphoma, TakeAim Leukemia, and TakeAim CLL.

What is Emavusertib?

Emavusertib (CA-4948) is one of the drug candidates in UCLA's pipeline.

How can I learn about UCLA's collaborations?

The article outlines various partner and scientific collaborations at UCLA.

What resources are available for patients?

UCLA provides an overview of patient resources and current studies.

Last updated: Oct 23, 2024